Message from the Dean
Greetings from the Dean of the School of Medicine/Graduate School of Medicine
On behalf of the Nagoya University School of Medicine and Graduate School of Medicine, I am honored to have this opportunity to say a few words of greeting.
The Nagoya University School of Medicine was originally founded in 1871 (Meiji year 4) by the Nagoya feudal clan as a temporary hospital and temporary medical school. With a history and traditions stretching back 140 years, it is one of the oldest medical schools in Japan. In 1939 the University became the seventh Imperial University in Japan, with faculties of medicine and science and engineering. In 1949, after World War II, it was restarted as Nagoya University under a new education system.
In 1997 the Department of Health Sciences was established; the School of Medicine thus came to comprise two faculties, Medicine and Health Sciences. Then, in 2000, Nagoya University completed organizational strengthening of its graduate schools and, as a graduate university, it restructured the Graduate School of Medicine by reorganizing the basic and clinical medicines into four research fields: Integrated Molecular Medicine, Cell Information Medicine, Function Construction Medicine and Health & Community Medicine. In the last school year, these four programs were merged into one program named the Program in Integrated Medicine, in which three divisions, the Division of Basic Medicine, the Division of Clinical Medicine, and the Division of Clinical Pharmacology, were established. For the Division of Clinical Pharmacology, we have just launched two new disciplines, Biostatistics and Toxicogenomics, to enhance drug discovery and clinical medicine research. Additionally, the Division of Clinical Pharmacology established new sub-divisions in collaboration with various partners, including Meijo University's Graduate School of Pharmacy, pharmaceutical companies such as Astellas Pharma Inc. under industry-academia partnership, and the Institute of Statistical Mathematics and the Pharmaceuticals and Medical Devices Agency, with the aim of strengthening the development of individuals with potential capability in drug discovery and those with the ability to accelerate clinical trials, because this is an area in which Japan lags behind other countries.
Simultaneously, with the reorganization of the Graduate School of Medicine as described above, we are improving the facilities that support the basis of our education and research, as a result of which the construction of the Graduate School of Medicine's research building No. 3 will be completed in June 2014. This building will include a dissection training room, a histological/pathological training room, a radioisotope center, and a common-use equipment center. The building will also provide space for various project-based studies, including those conducted by endowed chairs and by industry-academia collaborative sub-divisions. Biostatistics and Toxicogenomics, the new disciplines which will be established in the Division of Clinical Pharmacology as mentioned earlier, will also be housed in building No. 3, thus improving our education and study environment.
As one of the major missions of the Graduate School of Medicine from last year, we intend to accelerate the internationalization of the institution at the postgraduate level. We sent a group of about 10 researchers to the Medical University of Vienna in January 2013, and to the University of Adelaide in Australia last May, holding symposia and deepening our exchange. In November we visited the University of Freiburg in Germany and the University of Strasbourg in France to discuss cooperation. Due to the success of this, in March this year the president, vice-president and dean of the Faculty of Medicine from the University of Adelaide and the University of Freiburg gathered at Nagoya University's Graduate School of Medicine, and there concluded a cooperative agreement to promote graduate-level exchange. From now on we wish to broaden this cooperation to include universities in the USA as well.
We aim to have a School and Graduate School of Medicine full of vitality, and intend to put all possible effort into achieving this. We appreciate your advice and support.
Masahide TAKAHASHI, MD, PhD
Dean of the School of Medicine and Graduate School of Medicine,
Fields of Specialization
1. Experimental Pathology
2. Tumor Biology
3. Molecular Neurobiology
1. Molecular mechanisms of cancer invasion and metastasis
2. Mechanisms of anticancer drug resistance
3. Development of the nervous system and the molecular pathogenesis of neuropsychiatric disorders
1. Ishida-Takagishi, M., Enomoto, A., Asai, N., Ushida, K., Watanabe, T., Hasimoto, T., Kato, T., Weng, L., Matsumoto, S., Asai, M.,
Murakumo, y., Kaibuchi, K., Kikuchi, A. and Takahashi, M.
The Dvl-associated protein Daple controls the non-canonical Wnt/Rac pathway and cell motility. Nature Commun. (2012)
2. Enomoto, A., Asai, N., Namba, T., Wang, Y., Kato, T., Tanaka, M., Tatsumi, H., Taya, S., Tsuboi, D., Kuroda, K., Kaneko, N., Sawamoto, K.,
Miyamoto, R., Jijiwa, M., Murakumo, Y., Sokabe, M., Seki, T., Kaibuchi, K. and Takahashi, M.
Roles of Disrupted-in-Schizophrenia 1-interacting protein Girdin in postnatal development of the dentate gyrus. Neuron 63: 774-787 (2009).
3. Kitamura, T., Asai, N., Enomoto, A., Maeda, K., Kato, T., Ishida, M., Jiang, P., Watanabe, T., Usukura, J., Kondo, T., Costantini,
F., Murohara, T. and Takahashi, M.
Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nature Cell Biol., 10:329-337 (2008).
4. Enomoto, A., Murakami, H., Asai, N., Morone, N., Watanabe, T., Kawai, K., Murakumo, Y., Usukura, J., Kaibuchi, K., and Takahashi, M.
Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev. Cell 9: 389-402 (2005).
5. Klein, R.D., Sherman, D., Ho, W.-H., Stone, D., Bennett, G. L., Moffat, B., Vandlen, R., Simmons, L., Gu, Q., Hongo, J.-A., Devaux, B.,
Poulsen, K., Armanini, M., Nozaki, C., Asai, N., Goddard, A., Phillips, H., Henderson, C. E., Takahashi, M. and Rosenthal, A.
A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. Nature 387: 717-721 (1997).
6. Asai, N., Iwashita, T., Matsuyama, M. and Takahashi, M.
Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell. Biol. 15: 1613-1619 (1995).
7. Takahashi, M., Ritz, J. and Cooper, G.M.
Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42: 581-588 (1985).